Comparative Pharmacology
Head-to-head clinical analysis: ANAFRANIL versus JANIMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANAFRANIL versus JANIMINE.
ANAFRANIL vs JANIMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clomipramine is a tricyclic antidepressant (TCA) that inhibits the reuptake of serotonin and norepinephrine, with a higher potency for serotonin reuptake inhibition. It also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking properties.
Imipramine inhibits the reuptake of norepinephrine and serotonin at nerve terminals, potentiating their neurotransmission. It also has anticholinergic and antihistaminergic effects.
Initial: 25 mg PO tid; increase gradually to 100-150 mg/day. Maximum: 250 mg/day. Maintenance: lowest effective dose.
25-50 mg orally 2-4 times daily; maintenance 150 mg/day divided
None Documented
None Documented
Terminal elimination half-life of clomipramine is approximately 21-26 hours; its active metabolite, desmethylclomipramine, has a half-life of approximately 36-42 hours. Steady-state is achieved within 7-14 days.
5-15 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for steady state.
Renal (primarily as conjugated metabolites, ~60-70% over 72 hours); fecal (biliary excretion of ~10-20%); <2% excreted unchanged in urine.
Primarily renal (70-80% as metabolites, 5% unchanged); biliary/fecal (20-30% as metabolites).
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant